Abstract

Purpose. To compare biomechanical effect, riboflavin penetration and distribution in transepithelial corneal collagen cross-linking with iontophoresis (I-CXL), with standard cross linking (S-CXL) and current transepithelial protocol (TE-CXL). Materials and Methods. The study was divided into two different sections, considering, respectively, rabbit and human cadaver corneas. In both sections corneas were divided according to imbibition protocols and irradiation power. Imaging mass spectrometry by matrix-assisted laser desorption/ionization (MALDI-IMS) and stress-strain measurements were used. Forty-eight rabbit and twelve human cadaver corneas were evaluated. Results. MALDI-IMS showed a deep riboflavin penetration throughout the corneal layers with I-CXL, with a roughly lower concentration in the deepest layers when compared to S-CXL, whereas with TE-CXL penetration was considerably less. In rabbits, there was a significant increase (by 71.9% and P = 0.05) in corneal rigidity after I-CXL, when compared to controls. In humans, corneal rigidity increase was not significantly different among the subgroups. Conclusions. In rabbits, I-CXL induced a significant increase in corneal stiffness as well as better riboflavin penetration when compared to controls and TE-CXL but not to S-CXL. Stress-strain in human corneas did not show significant differences among techniques, possibly because of the small sample size of groups. In conclusion, I-CXL could be a valid alternative to S-CXL for riboflavin delivery in CXL, preserving the epithelium.

Highlights

  • Keratoconus is a slowly progressive, asymmetric, bilateral degenerative corneal disease [1]

  • Standard CXL (S-CXL) technique involves the removal of corneal epithelium to allow penetration of riboflavin

  • Corneal collagen cross-linking is a photochemical reaction aimed at increasing corneal rigidity via the formation intrafibrillar and interfibrillar covalent bonds

Read more

Summary

Introduction

Keratoconus is a slowly progressive, asymmetric, bilateral degenerative corneal disease [1]. Corneal collagen cross-linking (CXL) is presently the only treatment that can relent or arrest progressive ectasia [3,4,5] BioMed Research International reaction, catalyzed by riboflavin (vitamin B2), and it induces a biomechanical response that enhances corneal stiffness and blocks the progression of the disease [3, 5,6,7]. This bears consequences on corneal biomechanics, with visual acuity, morphological and functional indices improving up to 48 months postoperatively and possibly more [3,4,5]. In the attempt to avoid these disadvantages, transepithelial CXL (TE-CXL) technique was introduced, with a protocol based on a specially formulated riboflavin solution, Ricrolin TE (Sooft, Montegiorgio, FM, Italy), featuring two enhancers, trometamol and sodium EDTA, in order to improve stromal penetration

Objectives
Methods
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call